- Home
- MRNA vs CHRW Comparison
MRNA vs CHRW Comparison
Compare MRNA & CHRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRNA | CHRW |
|---|---|---|
| Founded | 2010 | 1905 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oil Refining/Marketing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.5B | 23.0B |
| IPO Year | 2018 | 1997 |
Fundamental Metrics
Financial Performance| Metric | MRNA | CHRW |
|---|---|---|
| Price | $45.33 | $177.38 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 20 |
| Target Price | $34.27 | ★ $181.05 |
| AVG Volume (30 Days) | ★ 4.9M | 1.7M |
| Earning Date | 05-01-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.35% |
| EPS Growth | 21.77 | ★ 25.13 |
| EPS | N/A | ★ 4.83 |
| Revenue | ★ $19,263,000,000.00 | $14,869,380,000.00 |
| Revenue This Year | $9.36 | $5.07 |
| Revenue Next Year | $15.43 | $6.26 |
| P/E Ratio | ★ N/A | $37.41 |
| Revenue Growth | ★ 4.29 | N/A |
| 52 Week Low | $22.28 | $86.58 |
| 52 Week High | $59.55 | $203.34 |
Technical Indicators
Market Signals| Indicator | MRNA | CHRW |
|---|---|---|
| Relative Strength Index (RSI) | 34.62 | 49.08 |
| Support Level | $23.52 | $172.61 |
| Resistance Level | $55.36 | $187.09 |
| Average True Range (ATR) | 2.87 | 6.00 |
| MACD | -1.00 | 0.38 |
| Stochastic Oscillator | 13.14 | 51.52 |
Price Performance
Historical ComparisonAbout MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About CHRW C.H. Robinson Worldwide Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (about 60% of net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm operates a large air and ocean forwarding division (30%), which has grown organically and via tuck-in acquisitions over the years. The remainder of revenue consists of transportation management services and a legacy produce-sourcing operation.